Nivolumab plus ipilimumab in advanced non-small-cell lung cancer

Cited by (1,003)

Items 101–200 of 1,003

1. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer
   William T. Atchley, Carolina Álvarez, Shruti Saxena, Todd A. Schwartz, Rumey C. Ishizawar, Kunal P. Patel, M. Patricia Rivera · 2021 · CHEST Journal
2. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
   Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan A. Żurawski, Juliana Janoski De Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Óscar Juan et al. · 2021 · ESMO Open
3. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
   Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, Parsa Modareszadeh, Eranda Berisha, Parinaz Sadat Alemi, Maria del Carmen Chacon Castro, Alexander R. Deese, Zhang Li · 2022 · Cancers
4. Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
   Joseph Jonathan Zhao, Dominic Wei Ting Yap, Yiong Huak Chan, Benjamin Kye Jyn Tan, Chong Boon Teo, Nicholas L. X. Syn, Elizabeth Catherine Smyth, Yu Yang Soon, Raghav Sundar · 2021 · Journal of Clinical Oncology
5. Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
   Dovedi, Simon J., Elder, Matthew J., Yang, Chunning, Sitnikova, Suzanne I., Irving, Lorraine, Hansen, Anna, Hair, James, Jones, Des C., Hasani, Sumati, Wang, Bo et al. · 2021 · Cancer Discovery
6. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
   Steven Francis Powell, Delvys Rodríguez‐Abreu, Corey Jay Langer, Ali Tafreshi, Luis G Paz-Ares, Hans‐Georg Kopp, Jerónimo Rafael Rodríguez‐Cid, Dariusz Mirosław Kowalski, Ying Cheng, Takayasu Kurata et al. · 2021 · Journal of Thoracic Oncology
7. Immunotherapy for Glioblastoma: Current Progress and Challenges
   Miranda W. Yu, Daniela F. Quail · 2021 · Frontiers in Immunology
8. Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
   Keisuke Onoi, Yusuke Chihara, Junji Uchino, Takayuki Shimamoto, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama · 2020 · Journal of Clinical Medicine
9. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
   Edward S. Kim, Vamsidhar Velcheti, Tarek M. Mekhail, Cindy Yun, Sarah M. Shagan, Sylvia Hu, Young Kwang Chae, Ticiana A.B. Leal, Jonathan E. Dowell, Michaela L. Tsai et al. · 2022 · Nature Medicine
10. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
    Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher M. Attwood, Sebastiano Battaglia, Saby George, Gurkamal S. Chatta, Igor J. Puzanov et al. · 2021 · Nature Communications
11. The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances
    James Robert Janopaul-Naylor, Yang Shen, David C. Qian, Zachary S. Buchwald · 2021 · International Journal of Molecular Sciences
12. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
    Jii Bum Lee, Hye Ryun Kim, Sang‐Jun Ha · 2022 · Immune Network
13. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
    Xiong, Anwen, Wang, Lei, Chen, Jianhua, Wu, Lin, Liu, Baogang, Yao, Jun, Zhong, Hua, Li, Jie, Cheng, Ying, Sun, Yulan et al. · 2025 · The Lancet
14. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
    Zhenyi Niu, Runsen Jin, Yan Zhang, Hecheng Li · 2022 · Signal Transduction and Targeted Therapy
15. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Sarah Cook, Vanessa Samuel, Daniel E. Meyers, Igor Stukalin, Ishjot Litt, Randeep S. Sangha, Don G. Morris, Daniel Yick Chin Heng, Aliyah Pabani, Michelle Liane Dean et al. · 2024 · JAMA Network Open
16. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
    Jordi Remón, Francesco Passiglia, Myung‐Ju Ahn, Fabrice Barlési, Patrick M. Forde, Edward B. Garon, Scott N. Gettinger, Sarah B. Goldberg, Roy S. Herbst, Leora Horn et al. · 2020 · Journal of Thoracic Oncology
17. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
    Samuel I. Kim, Christopher R. Cassella, Katelyn T. Byrne · 2021 · Frontiers in Immunology
18. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study
    Matteo Santoni, Alessandro Rizzo, Veronica Mollica, Marc Ryan Matrana, Matteo Rosellini, Luca Faloppi, Andrea Marchetti, Nicola Battelli, Francesco Massari · 2022 · Critical Reviews in Oncology/Hematology
19. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
    Lorenza Maria Landi, Federica D’Incà, Alain Jonathan Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta et al. · 2019 · Journal for ImmunoTherapy of Cancer
20. Genomic instability, inflammatory signaling and response to cancer immunotherapy
    Chen, Mengting, Linstra, Renske, van Vugt, Marcel A.T.M. · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
21. A gut microbial signature for combination immune checkpoint blockade across cancer types
    Gunjur, Ashray, Shao, Yan, Rozday, Timothy, Klein, Oliver, Mu, Andre, Haak, Bastiaan W., Markman, Ben, Kee, Damien, Carlino, Matteo S., Underhill, Craig et al. · 2024 · Nature Medicine
22. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
    Joshua E. Reuss, Valsamo Anagnostou, Tricia R. Cottrell, Kellie Nicole Smith, Franco Verde, MARIANNA L. ZAHURAK, Mara R. Lanis, Joseph Christopher Murray, Hok Yee Chan, Caroline G. McCarthy et al. · 2020 · Journal for ImmunoTherapy of Cancer
23. Tumour mutational burden: clinical utility, challenges and emerging improvements
    Jan Budczies, Daniel N. Kazdal, Michael Menzel, Susanne Beck, Klaus Kluck, Christian Altbürger, Constantin Schwab, Michael Allgäuer, Aysel Ahadova, Matthias Kloor et al. · 2024 · Nature Reviews Clinical Oncology
24. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
    Hafiza Padinharayil, Jinsu Varghese, Mithun Chacko John, Golgodu Krishnamurthy Rajanikant, Cornelia M. Wilson, Minnatallah Al-Yozbaki, Kaviyarasi Renu, Saikat Dewanjee, Rupa Sanyal, Abhijit Dey et al. · 2022 · Genes & Diseases
25. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722
    Tony S.K. Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi-Long Lung Cancer Wu, Justin F. Gainor, Se‐Hoon Lee, Chao‐Hua Chiu et al. · 2024 · Journal of Clinical Oncology
26. Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
    Jin U. Kang, Chao Zhang, Wen‐Zhao Zhong · 2021 · 癌症：英文版
27. Immune escape: A critical hallmark in solid tumors
    Keywan Mortezaee · 2020 · Life Sciences
28. Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis
    Kikkie Poels, Mandy M. T. van Leent, C. Boutros, Hubert Tissot, Séverine Roy, Anu E. Meerwaldt, Yohana C. Toner, Myrthe E. Reiche, Pascal J. H. Kusters, Tsveta S. Malinova et al. · 2020 · JACC CardioOncology
29. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
    Itziar Otano, Alvaro Conrado Ucero, Jon Zugazagoitia, Luis G Paz-Ares · 2023 · Nature Reviews Clinical Oncology
30. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
    Wolfgang Michael Brueckl, Joachim Hans Ficker, Gloria Zeitler · 2020 · BMC Cancer
31. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
    Giuseppe Viscardi, Antonino Carmelo Tralongo, Francesco Massari, Matteo Lambertini, Veronica Mollica, Alessandro Rizzo, Francesca Comito, Raimondo Di Liello, Salvatore Alfieri, Martina Imbimbo et al. · 2022 · European Journal of Cancer
32. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Jong Yeob Kim, Andreas Kronbichler, Michael Eisenhut, Sung Hwi Hong, Hans J. van der Vliet, Jeonghyun Kang, Jae Il Shin, Gabriele Gamerith · 2019 · Cancers
33. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
    Gaopeng Li, Jae Eun Choi, Ilona Kryczek, Yilun Sun, Peng Liao, Shasha Li, Shuang Wei, Sara Grove, Linda Vatan, Reagan Nelson et al. · 2023 · Cancer Cell
34. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
    David Planchard, Niels Reinmuth, С. В. Орлов, Jürgen R. Fischer, Shunichi Sugawara, Sławomir Mańdziuk, Diego Márquez-Medina, Silvia Novello, Yuichiro Takeda, Ross Andrew Soo et al. · 2020 · Annals of Oncology
35. The New Era of Immunotherapy in Gastric Cancer
    Shogo Takei, Akihito Kawazoe, Kohei Shitara · 2022 · Cancers
36. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
    Charu Aggarwal, Amy Prawira, Scott Joseph Antonia, Osama E. Rahma, Anthony W. Tolcher, Roger B. Cohen, Yanyan Lou, Ralph J. Hauke, Nicholas J. Vogelzang, Dan Paul Zandberg et al. · 2022 · Journal for ImmunoTherapy of Cancer
37. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
    Andrea J. Bullock, Benjamin L. Schlechter, Marwan Fakih, Apostolia Maria Tsimberidou, Joseph Elan Grossman, Michael S. Gordon, Breelyn Ann Wilky, Agustin Pimentel, Daruka Mahadevan, Ani Sarkis Balmanoukian et al. · 2024 · Nature Medicine
38. Enhancing immunotherapy with tumour-responsive nanomaterials
    Stephen W. Linderman, Louis B. DeRidder, Lucía Sanjurjo, Michael Bonner Foote, Marı́a José Alonso, Ameya R. Kirtane, Róbert Langer, Giovanni Traverso · 2025 · Nature Reviews Clinical Oncology
39. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
    Hwang, Michael, Canzoniero, Jenna Vanliere, Rosner, Samuel, Zhang, Guangfan, White, James R, Belcaid, Zineb, Cherry, Christopher, Balan, Archana, Pereira, Gavin, Curry, Alexandria et al. · 2022 · Journal for ImmunoTherapy of Cancer
40. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
    Matteo Santoni, Alessandro Rizzo, Jakub Kucharz, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, Fernando Sabino Marques Monteiro, Andrey Soares, Javier Molina‐Cerrillo et al. · 2023 · Cancer Immunology Immunotherapy
41. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
    Molina-Arcas, Miriam, Downward, Julian · 2024 · Cancer Cell
42. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study
    Christine M. Bestvina, Kelli B. Pointer, Theodore G Karrison, Hania Al‐Hallaq, Philip C. Hoffman, Michael J. Jelinek, Aditya Juloori, J.M. Melotek, Septimiu Dan Murgu, J. Partouche et al. · 2021 · Journal of Thoracic Oncology
43. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial
    Sungjune Kim, Evan John Wuthrick, Dukagjin M. Blakaj, Zeynep Eroglu, Claire F. Verschraegen, Ram Thapa, Matthew N. Mills, Khaled Nabil Dibs, Casey L. Liveringhouse, Jeffery Scott Russell et al. · 2022 · The Lancet
44. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
    Jingjing Qu, Quanhui Mei, Lijun Chen, Jianying Zhou · 2020 · Cancer Immunology Immunotherapy
45. First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
    Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, Francesco Passiglia, Francesca Mazzoni, Rossana Berardi, Claudia Proto, Fabiana Letizia Cecere, Sara Pilotto, Vieri Scotti et al. · 2020 · European Journal of Cancer
46. An update on the immune landscape in lung and head and neck cancers
    Jennifer Wilkinson Carlisle, Conor Ernst Steuer, Taofeek Kunle Owonikoko, Nabil F. Saba · 2020 · CA A Cancer Journal for Clinicians
47. Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis
    Lihui Liu, Hua Bai, Chao Wang, Samuel Seery, Zhijie Wang, Jianchun Duan, Sini Li, Pei Xue, Guoqiang Wang, Yiting Sun et al. · 2021 · Journal of Thoracic Oncology
48. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
    Wong, Jeffrey Sum Lung, Kwok, Gerry Gin Wai, Tang, Vikki, Li, Bryan Cho Wing, Leung, Roland, Chiu, Joanne, Ma, Ka Wing, She, Wong Hoi, Tsang, Josephine, Lo, Chung Mau et al. · 2021 · Journal for ImmunoTherapy of Cancer
49. Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress
    Misty Dawn Shields, Julian Andres Marin-Acevedo, Bruna Pellini · 2021 · American Society of Clinical Oncology Educational Book
50. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
    Huang, Mu-Yang, Jiang, Xiao-Ming, Wang, Bing-Lin, Sun, Yang, Lu, Jin-Jian · 2021 · Pharmacology & Therapeutics
51. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
    Liansha Tang, Jialing Wang, Nan Lin, Yuwen Zhou, Wenbo He, Jiyan Liu, Xuelei Ma · 2021 · Frontiers in Immunology
52. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy
    Charu Aggarwal, Rotem Ben‐Shachar, Yinjie Gao, Seung Won Hyun, Zachary T. Rivers, Carrie Epstein, Kristiyana Kaneva, Chithra Sangli, Halla Sayed Nimeiri, Jyoti D. Patel · 2023 · JAMA Network Open
53. Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
    Omid Kooshkaki, Afshin Derakhshani, Negar Hosseinkhani, Mitra Torabi, Sahar Safaei, Oronzo Brunetti, Vito Racanelli, Nicola Silvestris, Behzad Baradaran · 2020 · International Journal of Molecular Sciences
54. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer
    Lorenzo Federico, Daniel James McGrail, Salah-Eddine Bentebibel, Cara Haymaker, A. Ravelli, Marie‐Andrée Forget, Tatiana V. Karpinets, Peixin Jiang, Alexandre Reuben, Marcelo Vailati Negrao et al. · 2021 · Annals of Oncology
55. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors
    Paul W. Sperduto, Brian S. De, Jing Li, David James Carpenter, John P. Kirkpatrick, Michael Milligan, Helen Alice Shih, Tuğçe Kütük, Rupesh R Kotecha, Hajime Higaki et al. · 2022 · International Journal of Radiation Oncology*Biology*Physics
56. The Significance of SPP1 in Lung Cancers and Its Impact as a Marker for Protumor Tumor-Associated Macrophages
    Eri Matsubara, Hiromu Yano, Cheng Pan, Yoshihiro Komohara, Yukio Fujiwara, Shukang Zhao, Yusuke Shinchi, Daisuke Kurotaki, Makoto Suzuki · 2023 · Cancers
57. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers
    Hao‐Xiang Wu, Zixian Wang, Qi Zhao, Dongliang Chen, Ming-Ming He, Lu-Ping Yang, Yingnan Wang, Ying Jin, Chao Ren, Hui Luo et al. · 2019 · Annals of Translational Medicine
58. The current knowledge concerning solid cancer and therapy
    Masoud Najafi, Jamal Majidpoor, Heidar Toolee, Keywan Mortezaee · 2021 · Journal of Biochemical and Molecular Toxicology
59. Deep Learning Model for Predicting Immunotherapy Response in Advanced Non−Small Cell Lung Cancer
    Mehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, Joao V. Alessi, Alessio Cortellini, Fabrizio Citarella, Lorenzo Nibid, Giuseppe Perrone, Elio Adib, Claudia Angela Maria Fulgenzi et al. · 2024 · JAMA Oncology
60. Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials
    Bharat Goel, Anoop Kumar Tiwari, Rajeev Pandey, Akhand Pratap Singh, Sujeet Kumar, Abhιshek Sinha, Shreyans Kumar Jain, Arun Khattri · 2022 · Translational Oncology
61. Increasing cure rates of solid tumors by immune checkpoint inhibitors
    Weijie Ma, Ruobing Xue, Zheng Gang Zhu, Hizra Farrukh, Wenru Song, Tianhong Li, Lei Zheng, Chong-xian Pan · 2023 · Experimental Hematology and Oncology
62. Mechanisms of resistance to immune checkpoint inhibitors
    Joji Nagasaki, Takamasa Ishino, Yosuke Togashi · 2022 · Cancer Science
63. Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives
    Sawsan Sudqi Said, Wisam Nabeel Ibrahim · 2023 · Pharmaceutics
64. Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
    Yuan Cheng, Tao Zhang, Qing Xu · 2021 · MedComm
65. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
    Nassar, Amin H., Adib, Elio, Abou Alaiwi, Sarah, El Zarif, Talal, Groha, Stefan, Akl, Elie W., Nuzzo, Pier Vitale, Mouhieddine, Tarek H., Perea-Chamblee, Tomin, Taraszka, Kodi et al. · 2022 · Cancer Cell
66. The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
    Antonio Galvano, Valerio Gristina, Umberto Malapelle, Pasquale Pisapia, Francesco Pepe, Nadia Barraco, Marta Castiglia, Alessandro Perez, Christian Diego Rolfo, Giancarlo Troncone et al. · 2021 · ESMO Open
67. A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed
    Shuncong Wang, Yewei Liu, Yuanbo Feng, Jian Zhang, Johannes V. Swinnen, Yue Li, Yicheng Ni · 2019 · Cancers
68. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
    Elio Adib, Amin H. Nassar, Elie W. Akl, Sarah Abou Alaiwi, Pier Vitale Nuzzo, Tarek H. Mouhieddine, Guru Sonpavde, Robert I. Haddad, Kent William Mouw, Marios Giannakis et al. · 2021 · Clinical Cancer Research
69. Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
    Haiyang Guo, Jun Zhang, Chao Qin, Hang Yan, Tao Liu, Haiyang Hu, Shengjie Tang, Shoujun Tang, Haining Zhou · 2022 · Cells
70. Predictive biomarkers for response to immune checkpoint inhibition
    Benjamin Shum, James Larkin, Samra Turajlic · 2021 · Seminars in Cancer Biology
71. Combinatorial therapy in tumor microenvironment: Where do we stand?
    Smita Kumari, Dia Advani, Sudhanshu Sharma, Rashmi K. Ambasta, Pravir Kumar · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
72. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
    Solange Peters, Rafał Dziadziuszko, Alessandro Morabito, Enriqueta Felip, Shirish M. Gadgeel, Parneet Kaur Cheema, Manuel Cobo, Zoran Gojko Andric, Carlos H. Barrios, Masafumi Yamaguchi et al. · 2022 · Nature Medicine
73. Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
    Deep Shah, Brian W. Soper, Lindsay S. Shopland · 2023 · Frontiers in Immunology
74. Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
    Peng Ouyang, Lijuan Wang, Jianlong Wu, Yao Tian, Caiyun Chen, Dengsheng Li, Zengxi Yao, Ruichang Chen, Guoan Xiang, Jin Gong et al. · 2024 · Frontiers in Immunology
75. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials
    Borghaei, Hossein, Langer, Corey J., Paz‐Ares, Luis, Rodríguez‐Abreu, Delvys, Halmos, Balazs, Garassino, Marina C., Houghton, Baerin, Kurata, Takayasu, Cheng, Ying, Lin, Jianxin et al. · 2020 · Cancer
76. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy
    Marwan Fakih, Jaideep Singh Sandhu, Dean W. Lim, Xiaochen Li, Sierra Li, Chongkai Wang · 2023 · JAMA Oncology
77. Immune checkpoint inhibitors: breakthroughs in cancer treatment
    Xueqing Kong, Jinyi Zhang, Shuwei Chen, Xianyang Wang, Qing Xi, Han Shen, Rongxin Zhang · 2024 · Cancer Biology and Medicine
78. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
    Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Ana Baramidze, Davit Giorgadze, Konstantin Penkov, Константин Константинович Лактионов, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova et al. · 2023 · Journal of Thoracic Oncology
79. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
    Katrin Pansy, Barbara Uhl, Jelena Krstić, Marta Szmyra, Karoline Fechter, Ana Santiso, Lea Thüminger, Hildegard Greinix, Julia Kargl, Katharina Theresa Prochazka et al. · 2021 · International Journal of Molecular Sciences
80. Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis
    Arsen Osipov, Su Jin Lim, Aleksandra Popović, Nilofer Saba Azad, Daniel A. Laheru, Lei Zheng, Elizabeth M. Jaffee, Hao Wang, Mark M. Yarchoan · 2020 · Clinical Cancer Research
81. Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer
    Miho Oka, Liu Xu, Toshihiro Suzuki, Toshiaki Yoshikawa, Hiromi Sakamoto, Hayato Uemura, Akiyasu C. Yoshizawa, Yutaka Suzuki, Tetsuya Nakatsura, Yasushi Ishihama et al. · 2021 · Genome biology
82. Agonistic CD40 Antibodies in Cancer Treatment
    Dijana Djureinovic, Meina Wang, Harriet M. Kluger · 2021 · Cancers
83. Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
    Alessandro Rizzo, Antonio Cusmai, Francesco Giovannelli, Silvana Acquafredda, Lucia Rinaldi, Andrea Misino, Elisabetta Sara Montagna, Valentina Ungaro, Mariagrazia Lorusso, Gennaro Palmiotti · 2022 · Cancers
84. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors
    Timothy Anthony Yap, Aditya Bardia, Michael Dvorkin, Matthew D. Galsky, Joseph Thaddeus Beck, David R. Wise, O. B. Karyakin, Gábor Rubovszky, Nikolay Viktorovich Kislov, Kristoffer Staal Rohrberg et al. · 2022 · JAMA Oncology
85. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study
    Albrecht Stenzinger, Volker Endris, Jan Budczies, Sabine Merkelbach‐Bruse, Daniel N. Kazdal, Wolfgang Dietmaier, Nicole Pfarr, Udo Siebolts, Michael Hummel, Sylvia Herold et al. · 2020 · Journal of Thoracic Oncology
86. LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
    Landon Carter Brown, Matthew D. Tucker, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew Labriola, Rajan T. Gupta, Daniele Marin, Yuan Shan Wu et al. · 2021 · Journal for ImmunoTherapy of Cancer
87. Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
    Jee Hye Kang, Jeffrey A. Bluestone, Arabella Young · 2021 · Trends in Immunology
88. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
    Duerinck, Johnny, Schwarze, Julia Katharina, Awada, Gil, Tijtgat, Jens, Vaeyens, Freya, Bertels, Cleo, Geens, Wietse, Klein, Samuel, Seynaeve, Laura, Cras, Louise et al. · 2021 · Journal for ImmunoTherapy of Cancer
89. Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
    Paula Dobosz, Maria Stępień, Anna Golke, Tomasz Dzieciątkowski · 2022 · International Journal of Molecular Sciences
90. Immunotherapy in Small Cell Lung Cancer
    Giovanna Esposito, Giuliano Palumbo, Guido Carillio, Anna Manzo, Agnese Montanino, Vincenzo Sforza, Raffaele Costanzo, Claudia Sandomenico, Carmine La Manna, Nicola Martucci et al. · 2020 · Cancers
91. Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
    Damian Muszak, Ewa Surmiak, Jacek Plewka, Katarzyna Magiera‐Mularz, Justyna Kocik-Krol, Bogdan Musielak, Dominik Sala, Radosław Kitel, Małgorzata Stec, Kazimierz Węglarczyk et al. · 2021 · Journal of Medicinal Chemistry
92. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
    Stanley I. Gutiontov, William Tyler Turchan, Liam Flinn Spurr, Sherin Juliet Rouhani, Carolina Soto Chervin, George Steinhardt, Angela M. Lager, Pankhuri Wanjari, Renuka Malik, Philip P. Connell et al. · 2021 · Scientific Reports
93. The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy
    Matthew J. Woodall, Silke Neumann, Katrin Campbell, Sharon Tracy Pattison, Sarah L. Young · 2020 · Cancers
94. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
    Lucia Lisi, Pedro Miguel Lacal, Maria Martire, Pierluigi Navarra, Grazia Graziani · 2021 · Pharmacological Research
95. C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study
    Jakob Michael Riedl, Dominik Andreas Barth, Wolfgang Michael Brueckl, Gloria Zeitler, Vasile Foris, Stefanie Mollnar, Michael Stotz, Christopher H. Rossmann, Angelika Terbuch, Marija Balić et al. · 2020 · Cancers
96. Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis
    Sophia Heinrich, Amanda J. Craig, Lichun Ma, Bernd Heinrich, Tim F. Greten, Xin Wei Wang · 2020 · Journal of Hepatology
97. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    Laura Boyero, Amparo Sánchez-Gastaldo, Miriam D. Alonso, José Francisco Noguera-Uclés, Sonia Molina‐Pinelo, Reyes Bernabé · 2020 · Cancers
98. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer
    Scott N. Gettinger, Mary Weber Redman, Lyudmila A. Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence Howard Schwartz, Jeffrey D. Bradley, Thomas E. Stinchcombe, Natasha B. Leighl, Suresh S. Ramalingam et al. · 2021 · JAMA Oncology
99. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer
    Hanlin Yin, Ning Pu, Qiangda Chen, Jicheng Zhang, Guochao Zhao, Xuefeng Xu, Dansong Wang, Tiantao Kuang, Dayong Jin, Wenhui Lou et al. · 2021 · Cell Death and Disease
100. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
     Luis G Paz-Ares, Tudor–Eliade Ciuleanu, Manuel Cobo, Jaafar Bennouna, Michael Schenker, Ying Cheng, Óscar Juan, Hideaki Mizutani, Alejo Lingua, Felipe Reyes-Cosmelli et al. · 2022 · Journal of Thoracic Oncology